512 - Efficacy of Gepotidacin versus Nitrofurantoin in a Nitrofurantoin Not Susceptible Population: A Pooled Analysis of the EAGLE-2 and EAGLE-3 Randomized Controlled Trials in Uncomplicated Urinary Tract Infection

Saturday, October 19, 2024

11:06 AM – 11:18 AM US PT

Location: 403 A

Presenting Author(s)

Amanda Sheets, PhD

Director, Clinical Development
GSK, Collegeville, PA, USA
Collegeville, Pennsylvania, United States
SW

Sarah Watts, MSc

GSK
Brentford, England, United Kingdom
Nicole E. Scangarella-Oman, MS (she/her/hers)

Scientific Director
GlaxoSmithKline plc.
Collegeville, Pennsylvania, United States
DB

Deborah Butler, PharmD

VP & Head of Emerging Markets Regulatory Affairs at GSK
GSK
London, England, United Kingdom
JB

John Breton, MCM

GSK
Collegeville, Pennsylvania, United States
SJ

Salim Janmohamed, MD

GSK, Brentford, UK
Brentford, England, United Kingdom

Disclosure(s):

Jeremy Dennison, MD PhD: GSK: Employee, Stocks/Bonds (Public Company)

Amanda Sheets, PhD: GSK: Employee, Stocks/Bonds (Public Company)

Sarah Watts, MSc: GSK: Employee, Stocks/Bonds (Public Company)

Nicole E. Scangarella-Oman, MS: GSK: Employee, Stocks/Bonds (Public Company)

Deborah Butler, PharmD: GSK: Employee, Stocks/Bonds (Public Company)

John Breton, MCM: GSK: Employee, Stocks/Bonds (Public Company)

Salim Janmohamed, MD: GSK: Employee, Stocks/Bonds (Public Company)